标签归档：stat

STAT3-IN-1

发表于由
回复

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

STAT3-IN-1  纯度: 96.54%

STAT3-IN-1 (compound 7d) 是强效的、选择性的、口服有效的STAT3 的抑制剂，其在HT29 和MDA-MB 231 细胞中的 IC50 值分别为1.82 μM 和2.14 μM。STAT3-IN-1 (compound 7d) 可诱导肿瘤细胞凋亡。

STAT3-IN-1

STAT3-IN-1 Chemical Structure

CAS No. : 2059952-75-7

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥1570 In-stock
5 mg ￥1500 In-stock
10 mg ￥2400 In-stock
50 mg ￥6800 In-stock
100 mg ￥9800 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

STAT3-IN-1 相关产品

•相关化合物库:

  • Covalent Screening Library Plus
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Immunology/Inflammation Compound Library
  • JAK/STAT Compound Library
  • Kinase Inhibitor Library
  • Stem Cell Signaling Compound Library
  • Anti-Cancer Compound Library
  • Small Molecule Immuno-Oncology Compound Library
  • Anti-Aging Compound Library
  • Covalent Screening Library
  • Differentiation Inducing Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Transcription Factor Targeted Library
  • Anti-Liver Cancer Compound Library

生物活性

STAT3-IN-1 (compound 7d) is an excellent, selective and orally active STAT3 inhibitor, with IC50 values of 1.82 μM and 2.14 μM in HT29 and MDA-MB 231 cells, respectively. STAT3-IN-1 (compound 7d) induces tumor apoptosis[1].

IC50 & Target[1]

Stat-3

1.82 μM (IC50, in HT29 cells)

Stat-3

2.14 μM (IC50, in MDA-MB 231 cells)

体外研究
(In Vitro)

STAT3-IN-1 (compound 7d: 0-10 μM, 48 h) inhibits the STAT3 acetylation at lysine 685 and affected its specific genes expressions[1].
STAT3-IN-1 (compound 7d: 0-10 μM, 48 h) induces tumor cells apoptosis in MDA-MB-231 cells[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis[1]

Cell Line: MDA-MB-231 cell lines.
Concentration: 0-10 μM.
Incubation Time: 48 hours.
Result: The induced apoptosis rates (early and late apoptosis) at 1, 2, 5, 8 and 10 μM were 9.0%, 11.2%, 20.9%, 43.3% and 85.2% versus control 3.0%.

Western Blot Analysis[1]

Cell Line: MDA-MB-231 and HT-29 cell lines.
Concentration: 0-10 μM.
Incubation Time: 48 hours.
Result: Inhibited STAT3 acetylation and STAT3 tyrosine phosphorylation in MDA-MB-231 cells.
Increased the expressions of these tumor-suppressor genes (PTPN6 (SHP-1), CDKN2A and DLEC1) which were related to STAT3 acetylation at Lys685.

体内研究
(In Vivo)

STAT3-IN-1 (compound 7d: 10, 20 mg/kg, two weeks) arrests tumor growth with low toxicity in mouse-xenograft model[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Mouse-xenograft model bearing inoculation of mice breast cancer 4T1 cells[1].
Dosage: 10, 20 mg/kg.
Administration: Oral administration once every other day for two weeks.
Result: Arrested tumor growth with no obvious body weight loss.

分子量

475.53

Formula

C28H29NO6
CAS 号

2059952-75-7
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 125 mg/mL (262.86 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.1029 mL 10.5146 mL 21.0292 mL
5 mM 0.4206 mL 2.1029 mL 4.2058 mL
10 mM 0.2103 mL 1.0515 mL 2.1029 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: 6.25 mg/mL (13.14 mM); Suspended solution; Need ultrasonic

    此方案可获得 6.25 mg/mL (13.14 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例，取 100 μL 62.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Li S, et al. Discovery of oral-available resveratrol-caffeic acid based hybrids inhibiting acetylated and phosphorylated STAT3 protein. Eur J Med Chem. 2016 Nov 29;124:1006-1018.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

NT219

发表于由
回复

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

NT219 

NT219 是一种有效的胰岛素受体底物 1/2 (IRS1/2) 和 STAT3 的双重抑制剂。IRS1/2 和 STAT3 是受各种癌基因调控的主要信号连接。NT219 影响 IRS1/2 降解并抑制 STAT3 磷酸化。NT219 具有研究癌症疾病的潜力。

NT219

NT219 Chemical Structure

CAS No. : 1198078-60-2

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

NT219 is a potent and dual inhibitor of insulin receptor substrates 1/2 (IRS1/2) and STAT3. IRS1/2 and STAT3 are major signaling junctions regulated by various oncogenes. NT219 affects IRS1/2 degradation and inhibits STAT3 phosphorylation. NT219 has the potential for the research of cancer diseases[1].

分子量

412.26

Formula

C16H14BrNO5S
CAS 号

1198078-60-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Alberto Bessudo, et al. A phase 1/2 study with open-label, dose escalation phase followed by single-arm expansion at the maximum tolerated dose to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 injection alone and in combination with cetuximab in adults with advanced solid tumors and head and neck cancer.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

SC99

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

SC99  纯度: 99.07%

SC99 是口服有效的，选择性的 STAT3 抑制剂，靶向 JAK2-STAT3 途径。SC99 结合在 JAK2 的 ATP 结合袋中。SC99 抑制 JAK2 和 STAT3 的磷酸化，而对与 STAT3 信号相关的其他激酶没有影响。SC99 抑制血小板活化、聚集，并显示有效的抗骨髓瘤，抗血栓形成活性。

SC99

SC99 Chemical Structure

CAS No. : 882290-02-0

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥2750 In-stock
5 mg ￥2500 In-stock
10 mg ￥4000 In-stock
50 mg ￥11500 In-stock
100 mg ￥17500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

SC99 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Epigenetics Compound Library
  • Immunology/Inflammation Compound Library
  • JAK/STAT Compound Library
  • Kinase Inhibitor Library
  • Stem Cell Signaling Compound Library
  • Anti-Cancer Compound Library
  • Small Molecule Immuno-Oncology Compound Library
  • Anti-Aging Compound Library
  • Differentiation Inducing Compound Library
  • Reprogramming Compound Library
  • Anti-Cardiovascular Disease Compound Library
  • Orally Active Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Transcription Factor Targeted Library
  • Anti-Liver Cancer Compound Library

生物活性

SC99 is an orally active, selective STAT3 inhibitor targeting JAK2-STAT3 pathway. SC99 docks into the ATP-binding pocket of JAK2. SC99 inhibits phosphorylation of JAK2 and STAT3 with no effects on the other kinases associated with STAT3 signaling. SC99 inhibits platelet activation, aggregation and displays potent anti-myeloma, anti-thrombotic activities[1][2][3].

IC50 & Target

STAT3

 

JAK2

 

体外研究
(In Vitro)

SC99 (10 or 30 μM; for 72 hours) induces MM cell death[1].
SC99 (10 μM; 24 hours) decreases the p-STAT3 level but has no effects on total STAT3 expression. SC99 (2.5, 5, 10, 20 μM; for 60 mins) inhibits JAK2 phosphorylation in a concentration-dependent manner but does not inhibit the phosphorylation levels of AKT, ERK, mTOR or c-Src at a concentration up to 20 μM[1].
SC99 (1.25, 2.5, 5 μM; pre-treated for 10 min) inhibits collagen (2 μg/mL) and thrombin (0.02 U/mL) induced phosphorylation of STAT3 in a concentration-dependent manner[2].
SC99 (pre-treated for 2 hours) inhibits IL-6 (50 ng/ml; for 20 min) induced STAT3 nuclear translocation in OPM2 cells[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis[1]

Cell Line: Six multiple myeloma (MM) cell lines (LP1, JJN3, RPMI-8226, U266, OPM2 and OCI-MY5)
Concentration: 10 or 30 μM
Incubation Time: For 72 hours
Result: Induced MM cell death.

Apoptosis Analysis[1]

Cell Line: MM cell lines[1]
Concentration: 10 μM
Incubation Time: 24 hours
Result: Decreased the p-STAT3 level but had no effects on total STAT3 expression in all cell lines examined.

体内研究
(In Vivo)

SC99 (30 mg/kg; orally; daily; for continuous 14 or 28 days) delays myeloma tumor growth in xenograft mice models[1].
SC99 (5, 10, 15 mM, 15 μL; ICV) produces an effective inhibitory effect on the phosphorylation of JAK2 and STAT3 in middle cerebral artery occlusion and reperfusion (MCAO/R) model (adult male SD rats; 250-300 g). SC99 ameliorates neuronal apoptosis and degeneration, neurobehavioral deficits, inflammatory response and brain edema[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Nude mice with Human MM cells OPM2 or JJN3[1]
Dosage: 30 mg/kg
Administration: Orally; daily; for continuous 14 or 28 days
Result: Delayed myeloma tumor growth in xenograft mice models and suppressed tumor growth more than 40% in 14 days in the OPM2 model.

分子量

336.15

Formula

C15H8Cl2FN3O
CAS 号

882290-02-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 83.33 mg/mL (247.90 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.9749 mL 14.8743 mL 29.7486 mL
5 mM 0.5950 mL 2.9749 mL 5.9497 mL
10 mM 0.2975 mL 1.4874 mL 2.9749 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: 2.08 mg/mL (6.19 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.08 mg/mL (6.19 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2.08 mg/mL (6.19 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.08 mg/mL (6.19 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Zubin Zhang, et al. A novel small molecule agent displays potent anti-myeloma activity by inhibiting the JAK2-STAT3 signaling pathway. Oncotarget. 2016 Feb 23;7(8):9296-308.

    [2]. Zhuan Xu, et at. A novel STAT3 inhibitor negatively modulates platelet activation and aggregation. Acta Pharmacol Sin. 2017 May;38(5):651-659.

    [3]. Yiping Ding, et al. Effects of SC99 on cerebral ischemia-perfusion injury in rats: Selective modulation of microglia polarization to M2 phenotype via inhibiting JAK2-STAT3 pathway. Neurosci Res. 2019 May;142:58-68.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

APTSTAT3-9R

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

APTSTAT3-9R 

APTSTAT3-9R 是一种特定的 STAT3 结合肽，通过特异性阻断 STAT3 磷酸化来抑制 STAT3 激活和下游信号传导。APTSTAT3-9R 具有抗增殖作用和抗肿瘤活性。

APTSTAT3-9R

APTSTAT3-9R Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

APTSTAT3-9R, a specific STAT3-binding peptide, inhibits STAT3 activation and downstream signaling by specifically blocking STAT3 phosphorylation. APTSTAT3-9R exerts antiproliferative effects and antitumor activity[1].

IC50 & Target[1]

STAT3

 

体外研究
(In Vitro)

APTSTAT3-9R (7.5, 15, and 30 μmol/L; 6 hours) significantly reduces STAT3–DNA-binding activity in a dose-dependent manner in human lung carcinoma cells (A549)[1].
APTSTAT3-9R (30 μM; for 2 weeks) suppresses cell viability and proliferation of cancer cells and significantly suppresses colony formation. APTSTAT3-9R has IC50s of 10 to 20 μM in A549, B16F1 and HepG2 cells[1].
APTSTAT3-9R (7.5, 15, and 30 μmol/L; 6 hours) effectively inhibits phosphorylation of STAT3 but does not affect the level of AKT phosphorylation, indicating specificity of the aptide[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

APTSTAT3-9R (8 mg/kg in 50 μL; intratumorally injected every other day for a total of four injections) suppresses tumor growth in 6-week-old female BALB/c nude mice with A549 cells[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

4947.51

Formula

C223H330N80O51
Sequence

His-Gly-Phe-Gln-Trp-Pro-Gly-Ser-Trp-Thr-Trp-Glu-Asn-Gly-Lys-Trp-Thr-Trp-Lys-Gly-Ala-Tyr-Gln-Phe-Leu-Lys-Gly-Gly-Gly-Gly-Ser-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg
Sequence Shortening

HGFQWPGSWTWENGKWTWKGAYQFLKGGGGSRRRRRRRRR
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Daejin Kim, et al. A Specific STAT3-binding Peptide Exerts Antiproliferative Effects and Antitumor Activity by Inhibiting STAT3 Phosphorylation and Signaling. Cancer Res. 2014 Apr 15;74(8):2144-51.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

APTSTAT3-9R

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

APTSTAT3-9R 

APTSTAT3-9R 是一种特定的 STAT3 结合肽，通过特异性阻断 STAT3 磷酸化来抑制 STAT3 激活和下游信号传导。APTSTAT3-9R 具有抗增殖作用和抗肿瘤活性。

APTSTAT3-9R

APTSTAT3-9R Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

APTSTAT3-9R, a specific STAT3-binding peptide, inhibits STAT3 activation and downstream signaling by specifically blocking STAT3 phosphorylation. APTSTAT3-9R exerts antiproliferative effects and antitumor activity[1].

IC50 & Target[1]

STAT3

 

体外研究
(In Vitro)

APTSTAT3-9R (7.5, 15, and 30 μmol/L; 6 hours) significantly reduces STAT3–DNA-binding activity in a dose-dependent manner in human lung carcinoma cells (A549)[1].
APTSTAT3-9R (30 μM; for 2 weeks) suppresses cell viability and proliferation of cancer cells and significantly suppresses colony formation. APTSTAT3-9R has IC50s of 10 to 20 μM in A549, B16F1 and HepG2 cells[1].
APTSTAT3-9R (7.5, 15, and 30 μmol/L; 6 hours) effectively inhibits phosphorylation of STAT3 but does not affect the level of AKT phosphorylation, indicating specificity of the aptide[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

APTSTAT3-9R (8 mg/kg in 50 μL; intratumorally injected every other day for a total of four injections) suppresses tumor growth in 6-week-old female BALB/c nude mice with A549 cells[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

4947.51

Formula

C223H330N80O51
Sequence

His-Gly-Phe-Gln-Trp-Pro-Gly-Ser-Trp-Thr-Trp-Glu-Asn-Gly-Lys-Trp-Thr-Trp-Lys-Gly-Ala-Tyr-Gln-Phe-Leu-Lys-Gly-Gly-Gly-Gly-Ser-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg
Sequence Shortening

HGFQWPGSWTWENGKWTWKGAYQFLKGGGGSRRRRRRRRR
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Daejin Kim, et al. A Specific STAT3-binding Peptide Exerts Antiproliferative Effects and Antitumor Activity by Inhibiting STAT3 Phosphorylation and Signaling. Cancer Res. 2014 Apr 15;74(8):2144-51.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

APTSTAT3-9R

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

APTSTAT3-9R 

APTSTAT3-9R 是一种特定的 STAT3 结合肽，通过特异性阻断 STAT3 磷酸化来抑制 STAT3 激活和下游信号传导。APTSTAT3-9R 具有抗增殖作用和抗肿瘤活性。

APTSTAT3-9R

APTSTAT3-9R Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

APTSTAT3-9R, a specific STAT3-binding peptide, inhibits STAT3 activation and downstream signaling by specifically blocking STAT3 phosphorylation. APTSTAT3-9R exerts antiproliferative effects and antitumor activity[1].

IC50 & Target[1]

STAT3

 

体外研究
(In Vitro)

APTSTAT3-9R (7.5, 15, and 30 μmol/L; 6 hours) significantly reduces STAT3–DNA-binding activity in a dose-dependent manner in human lung carcinoma cells (A549)[1].
APTSTAT3-9R (30 μM; for 2 weeks) suppresses cell viability and proliferation of cancer cells and significantly suppresses colony formation. APTSTAT3-9R has IC50s of 10 to 20 μM in A549, B16F1 and HepG2 cells[1].
APTSTAT3-9R (7.5, 15, and 30 μmol/L; 6 hours) effectively inhibits phosphorylation of STAT3 but does not affect the level of AKT phosphorylation, indicating specificity of the aptide[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

APTSTAT3-9R (8 mg/kg in 50 μL; intratumorally injected every other day for a total of four injections) suppresses tumor growth in 6-week-old female BALB/c nude mice with A549 cells[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

4947.51

Formula

C223H330N80O51
Sequence

His-Gly-Phe-Gln-Trp-Pro-Gly-Ser-Trp-Thr-Trp-Glu-Asn-Gly-Lys-Trp-Thr-Trp-Lys-Gly-Ala-Tyr-Gln-Phe-Leu-Lys-Gly-Gly-Gly-Gly-Ser-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg
Sequence Shortening

HGFQWPGSWTWENGKWTWKGAYQFLKGGGGSRRRRRRRRR
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Daejin Kim, et al. A Specific STAT3-binding Peptide Exerts Antiproliferative Effects and Antitumor Activity by Inhibiting STAT3 Phosphorylation and Signaling. Cancer Res. 2014 Apr 15;74(8):2144-51.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea 

STAT3-IN-7 是一种 Sorafenib 的衍生物，可有效抑制 STAT3 的磷酸化。STAT3-IN-7 通过依赖 SHP-1 的 STAT3 失活诱导细胞凋亡 (apoptosis)，不抑制激酶活性，并具有抗癌作用。

1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea

1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea Chemical Structure

CAS No. : 1313019-65-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

STAT3-IN-7 is a Sorafenib analogue and potently inhibits the phosphorylation of STAT3. STAT3-IN-7 induces cell apoptosis through SHP-1 dependent STAT3 inactivation. STAT3-IN-7 does not inhibit kinase activity and has anticancer effects[1].

IC50 & Target[1]

p-STAT3

 

体外研究
(In Vitro)

STAT3-IN-7 (SC-1; 1-10 μM; 48 hours; breast cancer cells) treatment demonstrates dose-dependent suppression of cell viability in all tested breast cancer cells[1].
STAT3-IN-7 (SC-1; 1-10 μM; 36 hours; breast cancer cells) treatment induces potent apoptotic activity[1].
STAT3-IN-7 (SC-1; 1-10 μM; 36 hours; breast cancer cells) treatment shows downregulation of p-STAT3 and its downstream proteins cyclin D1 and survivin in a dose-dependent manner in breast cancer cell lines[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: HCC-1937, MDA-MB-231, MDA-MB-468, MDA-MB-453, SK-BR3 and MCF-7 cells
Concentration: 1 μM, 2 μM, 5 μM, 7.5 μM, 10 μM
Incubation Time: 48 hours
Result: Demonstrated dose-dependent suppression of cell viability in all tested breast cancer cells.

Apoptosis Analysis[1]

Cell Line: HCC-1937, MDA-MB-231, MDA-MB-468, MDA-MB-453, SK-BR3 and MCF-7 cells
Concentration: 1 μM, 2 μM, 5 μM, 7.5 μM, 10 μM
Incubation Time: 36 hours
Result: Induced potent apoptotic activity.

Western Blot Analysis[1]

Cell Line: HCC-1937, MDA-MB-231, MDA-MB-468, MDA-MB-453, SK-BR3 and MCF-7 cells
Concentration: 1 μM, 2 μM, 5 μM, 7.5 μM, 10 μM
Incubation Time: 36 hours
Result: Showed downregulation of p-STAT3 and its downstream proteins cyclin D1 and survivin in a dose-dependent manner in breast cancer cell lines.

体内研究
(In Vivo)

STAT3-IN-7 (10 mg/kg; oral gavage; daily; for 28 days; female NCr athymic nude mice) treatment shows efficacious antitumor activity and p-STAT3 downregulation in MDA-MB-468 xenograft tumors[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female NCr athymic nude mice (4-6 weeks of age) injected with breast cancer cells [1]
Dosage: 10 mg/kg
Administration: Oral gavage; daily; for 28 days
Result: Showed efficacious antitumor activity and p-STAT3 downregulation in MDA-MB-468 xenograft tumors.

分子量

431.80

Formula

C21H13ClF3N3O2
CAS 号

1313019-65-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Chun-Yu Liu, et al. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Breast Cancer Res. 2013;15(4):R63.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea 

STAT3-IN-7 是一种 Sorafenib 的衍生物，可有效抑制 STAT3 的磷酸化。STAT3-IN-7 通过依赖 SHP-1 的 STAT3 失活诱导细胞凋亡 (apoptosis)，不抑制激酶活性，并具有抗癌作用。

1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea

1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea Chemical Structure

CAS No. : 1313019-65-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

STAT3-IN-7 is a Sorafenib analogue and potently inhibits the phosphorylation of STAT3. STAT3-IN-7 induces cell apoptosis through SHP-1 dependent STAT3 inactivation. STAT3-IN-7 does not inhibit kinase activity and has anticancer effects[1].

IC50 & Target[1]

p-STAT3

 

体外研究
(In Vitro)

STAT3-IN-7 (SC-1; 1-10 μM; 48 hours; breast cancer cells) treatment demonstrates dose-dependent suppression of cell viability in all tested breast cancer cells[1].
STAT3-IN-7 (SC-1; 1-10 μM; 36 hours; breast cancer cells) treatment induces potent apoptotic activity[1].
STAT3-IN-7 (SC-1; 1-10 μM; 36 hours; breast cancer cells) treatment shows downregulation of p-STAT3 and its downstream proteins cyclin D1 and survivin in a dose-dependent manner in breast cancer cell lines[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: HCC-1937, MDA-MB-231, MDA-MB-468, MDA-MB-453, SK-BR3 and MCF-7 cells
Concentration: 1 μM, 2 μM, 5 μM, 7.5 μM, 10 μM
Incubation Time: 48 hours
Result: Demonstrated dose-dependent suppression of cell viability in all tested breast cancer cells.

Apoptosis Analysis[1]

Cell Line: HCC-1937, MDA-MB-231, MDA-MB-468, MDA-MB-453, SK-BR3 and MCF-7 cells
Concentration: 1 μM, 2 μM, 5 μM, 7.5 μM, 10 μM
Incubation Time: 36 hours
Result: Induced potent apoptotic activity.

Western Blot Analysis[1]

Cell Line: HCC-1937, MDA-MB-231, MDA-MB-468, MDA-MB-453, SK-BR3 and MCF-7 cells
Concentration: 1 μM, 2 μM, 5 μM, 7.5 μM, 10 μM
Incubation Time: 36 hours
Result: Showed downregulation of p-STAT3 and its downstream proteins cyclin D1 and survivin in a dose-dependent manner in breast cancer cell lines.

体内研究
(In Vivo)

STAT3-IN-7 (10 mg/kg; oral gavage; daily; for 28 days; female NCr athymic nude mice) treatment shows efficacious antitumor activity and p-STAT3 downregulation in MDA-MB-468 xenograft tumors[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female NCr athymic nude mice (4-6 weeks of age) injected with breast cancer cells [1]
Dosage: 10 mg/kg
Administration: Oral gavage; daily; for 28 days
Result: Showed efficacious antitumor activity and p-STAT3 downregulation in MDA-MB-468 xenograft tumors.

分子量

431.80

Formula

C21H13ClF3N3O2
CAS 号

1313019-65-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Chun-Yu Liu, et al. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Breast Cancer Res. 2013;15(4):R63.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea 

STAT3-IN-7 是一种 Sorafenib 的衍生物，可有效抑制 STAT3 的磷酸化。STAT3-IN-7 通过依赖 SHP-1 的 STAT3 失活诱导细胞凋亡 (apoptosis)，不抑制激酶活性，并具有抗癌作用。

1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea

1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea Chemical Structure

CAS No. : 1313019-65-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

STAT3-IN-7 is a Sorafenib analogue and potently inhibits the phosphorylation of STAT3. STAT3-IN-7 induces cell apoptosis through SHP-1 dependent STAT3 inactivation. STAT3-IN-7 does not inhibit kinase activity and has anticancer effects[1].

IC50 & Target[1]

p-STAT3

 

体外研究
(In Vitro)

STAT3-IN-7 (SC-1; 1-10 μM; 48 hours; breast cancer cells) treatment demonstrates dose-dependent suppression of cell viability in all tested breast cancer cells[1].
STAT3-IN-7 (SC-1; 1-10 μM; 36 hours; breast cancer cells) treatment induces potent apoptotic activity[1].
STAT3-IN-7 (SC-1; 1-10 μM; 36 hours; breast cancer cells) treatment shows downregulation of p-STAT3 and its downstream proteins cyclin D1 and survivin in a dose-dependent manner in breast cancer cell lines[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: HCC-1937, MDA-MB-231, MDA-MB-468, MDA-MB-453, SK-BR3 and MCF-7 cells
Concentration: 1 μM, 2 μM, 5 μM, 7.5 μM, 10 μM
Incubation Time: 48 hours
Result: Demonstrated dose-dependent suppression of cell viability in all tested breast cancer cells.

Apoptosis Analysis[1]

Cell Line: HCC-1937, MDA-MB-231, MDA-MB-468, MDA-MB-453, SK-BR3 and MCF-7 cells
Concentration: 1 μM, 2 μM, 5 μM, 7.5 μM, 10 μM
Incubation Time: 36 hours
Result: Induced potent apoptotic activity.

Western Blot Analysis[1]

Cell Line: HCC-1937, MDA-MB-231, MDA-MB-468, MDA-MB-453, SK-BR3 and MCF-7 cells
Concentration: 1 μM, 2 μM, 5 μM, 7.5 μM, 10 μM
Incubation Time: 36 hours
Result: Showed downregulation of p-STAT3 and its downstream proteins cyclin D1 and survivin in a dose-dependent manner in breast cancer cell lines.

体内研究
(In Vivo)

STAT3-IN-7 (10 mg/kg; oral gavage; daily; for 28 days; female NCr athymic nude mice) treatment shows efficacious antitumor activity and p-STAT3 downregulation in MDA-MB-468 xenograft tumors[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female NCr athymic nude mice (4-6 weeks of age) injected with breast cancer cells [1]
Dosage: 10 mg/kg
Administration: Oral gavage; daily; for 28 days
Result: Showed efficacious antitumor activity and p-STAT3 downregulation in MDA-MB-468 xenograft tumors.

分子量

431.80

Formula

C21H13ClF3N3O2
CAS 号

1313019-65-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Chun-Yu Liu, et al. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Breast Cancer Res. 2013;15(4):R63.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

SD-1029

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

SD-1029 

SD-1029 是一种 JAK2/STAT3 抑制剂。SD-1029 抑制 STAT3 核易位。SD-1029 抑制 JAK2 磷酸化，从而抑制 STAT3 激活。

SD-1029

SD-1029 Chemical Structure

CAS No. : 118372-34-2

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

SD-1029 is a JAK2/STAT3 inhibitor[1]. SD-1029 inhibits STAT3 nuclear translocation. SD-1029 is an inhibitor of STAT3 activation due to inhibition of JAK2 phosphorylation[2].

IC50 & Target[1]

STAT3

 

JAK2

 

体外研究
(In Vitro)

SD-1029 (10 μM) inhibits EGFP-Stat3 nuclear translocation in BHK-21 and U-2OS cells[1].
SD-1029 (5 and 10 μM; 24 hours) inhibits cell growth and induces apoptosis in OVCAR8TR ovarian cancer cells[1].
SD-1029 (10 μM; 24 hours) suppresses p-Stat3 levels in human breast and ovarian cancer cell lines[1].
SD-1029 inhibits not only JAK2 phosphorylation, but also the phosphorylation of STAT1 and STAT3. SD-1029 strongly inhibits Tyk2 phosphorylation, implicating both JAK2 and Tyk2 as upstream requirements for IL-23-induced IL-23R expression[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: OVCAR8TR ovarian cancer cells
Concentration: 5 and 10 μM
Incubation Time: 24 hours
Result: Down-regulated cell proliferation, and induced apoptotic cell death.
Treatment resulted in a marked, 20-fold induction of apoptosis in the OVCAR8TR cells that express constitutively activated Stat3.

Western Blot Analysis[1]

Cell Line: MDA-MB-468 and MDA435 (breast cancer), OV1063 (ovarian cancer), and the paclitaxel-resistant ovarian cancer daughter lines, SKOV-3TR and OVCAR8TR.
Concentration: 10 μM
Incubation Time: 24 hours
Result: Led to reduced levels of pStat3.

分子量

639.25

Formula

C25H32Br2Cl2N2O3
CAS 号

118372-34-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Zhenfeng Duan, et al. SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation. Clin Cancer Res. 2006 Nov 15;12(22):6844-52.

    [2]. Nor Fazila Che Mat, et al. Interleukin-23-induced interleukin-23 receptor subunit expression is mediated by the Janus kinase/signal transducer and activation of transcription pathway in human CD4 T cells. J Interferon Cytokine Res. 2011 Apr;31(4):363-71.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

SD-1029

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

SD-1029 

SD-1029 是一种 JAK2/STAT3 抑制剂。SD-1029 抑制 STAT3 核易位。SD-1029 抑制 JAK2 磷酸化，从而抑制 STAT3 激活。

SD-1029

SD-1029 Chemical Structure

CAS No. : 118372-34-2

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

SD-1029 is a JAK2/STAT3 inhibitor[1]. SD-1029 inhibits STAT3 nuclear translocation. SD-1029 is an inhibitor of STAT3 activation due to inhibition of JAK2 phosphorylation[2].

IC50 & Target[1]

STAT3

 

JAK2

 

体外研究
(In Vitro)

SD-1029 (10 μM) inhibits EGFP-Stat3 nuclear translocation in BHK-21 and U-2OS cells[1].
SD-1029 (5 and 10 μM; 24 hours) inhibits cell growth and induces apoptosis in OVCAR8TR ovarian cancer cells[1].
SD-1029 (10 μM; 24 hours) suppresses p-Stat3 levels in human breast and ovarian cancer cell lines[1].
SD-1029 inhibits not only JAK2 phosphorylation, but also the phosphorylation of STAT1 and STAT3. SD-1029 strongly inhibits Tyk2 phosphorylation, implicating both JAK2 and Tyk2 as upstream requirements for IL-23-induced IL-23R expression[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: OVCAR8TR ovarian cancer cells
Concentration: 5 and 10 μM
Incubation Time: 24 hours
Result: Down-regulated cell proliferation, and induced apoptotic cell death.
Treatment resulted in a marked, 20-fold induction of apoptosis in the OVCAR8TR cells that express constitutively activated Stat3.

Western Blot Analysis[1]

Cell Line: MDA-MB-468 and MDA435 (breast cancer), OV1063 (ovarian cancer), and the paclitaxel-resistant ovarian cancer daughter lines, SKOV-3TR and OVCAR8TR.
Concentration: 10 μM
Incubation Time: 24 hours
Result: Led to reduced levels of pStat3.

分子量

639.25

Formula

C25H32Br2Cl2N2O3
CAS 号

118372-34-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Zhenfeng Duan, et al. SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation. Clin Cancer Res. 2006 Nov 15;12(22):6844-52.

    [2]. Nor Fazila Che Mat, et al. Interleukin-23-induced interleukin-23 receptor subunit expression is mediated by the Janus kinase/signal transducer and activation of transcription pathway in human CD4 T cells. J Interferon Cytokine Res. 2011 Apr;31(4):363-71.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

SD-1029

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

SD-1029 

SD-1029 是一种 JAK2/STAT3 抑制剂。SD-1029 抑制 STAT3 核易位。SD-1029 抑制 JAK2 磷酸化，从而抑制 STAT3 激活。

SD-1029

SD-1029 Chemical Structure

CAS No. : 118372-34-2

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

SD-1029 is a JAK2/STAT3 inhibitor[1]. SD-1029 inhibits STAT3 nuclear translocation. SD-1029 is an inhibitor of STAT3 activation due to inhibition of JAK2 phosphorylation[2].

IC50 & Target[1]

STAT3

 

JAK2

 

体外研究
(In Vitro)

SD-1029 (10 μM) inhibits EGFP-Stat3 nuclear translocation in BHK-21 and U-2OS cells[1].
SD-1029 (5 and 10 μM; 24 hours) inhibits cell growth and induces apoptosis in OVCAR8TR ovarian cancer cells[1].
SD-1029 (10 μM; 24 hours) suppresses p-Stat3 levels in human breast and ovarian cancer cell lines[1].
SD-1029 inhibits not only JAK2 phosphorylation, but also the phosphorylation of STAT1 and STAT3. SD-1029 strongly inhibits Tyk2 phosphorylation, implicating both JAK2 and Tyk2 as upstream requirements for IL-23-induced IL-23R expression[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: OVCAR8TR ovarian cancer cells
Concentration: 5 and 10 μM
Incubation Time: 24 hours
Result: Down-regulated cell proliferation, and induced apoptotic cell death.
Treatment resulted in a marked, 20-fold induction of apoptosis in the OVCAR8TR cells that express constitutively activated Stat3.

Western Blot Analysis[1]

Cell Line: MDA-MB-468 and MDA435 (breast cancer), OV1063 (ovarian cancer), and the paclitaxel-resistant ovarian cancer daughter lines, SKOV-3TR and OVCAR8TR.
Concentration: 10 μM
Incubation Time: 24 hours
Result: Led to reduced levels of pStat3.

分子量

639.25

Formula

C25H32Br2Cl2N2O3
CAS 号

118372-34-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Zhenfeng Duan, et al. SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation. Clin Cancer Res. 2006 Nov 15;12(22):6844-52.

    [2]. Nor Fazila Che Mat, et al. Interleukin-23-induced interleukin-23 receptor subunit expression is mediated by the Janus kinase/signal transducer and activation of transcription pathway in human CD4 T cells. J Interferon Cytokine Res. 2011 Apr;31(4):363-71.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

C188(Synonyms: CPD188)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

C188 (Synonyms: CPD188)

C188是一种STAT3抑制剂，通过靶向STAT3 SH2结构域的肽结合口袋，抑制IL -6诱导的STAT3磷酸化和HepG2细胞的核易位。C188在体外诱导乳腺癌细胞MB-MDA-468 的凋亡中表现出较高的活性(EC50= 0.7 μM)。

C188(Synonyms: CPD188)

C188 Chemical Structure

CAS No. : 823828-18-8

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

C188 is a STAT3 inhibitor that inhibits IL-6-stimulated STAT3 phosphorylation and nuclear translocation in HepG2 cells by targeting STAT3 SH2 domain peptide-binding pocket. C188, in particular, was highly active in inducing apoptosis of the breast cancer cell line MB-MDA-468 in vitro (EC50= 0.7 μM).

分子量

433.45

Formula

C19H15NO7S2
CAS 号

823828-18-8
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Xu X, Kasembeli MM, Jiang X, Tweardy BJ, Tweardy DJ. Chemical probes that competitively and selectively inhibit Stat3 activation. PLoS One. 2009;4(3):e4783.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

C188(Synonyms: CPD188)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

C188 (Synonyms: CPD188)

C188是一种STAT3抑制剂，通过靶向STAT3 SH2结构域的肽结合口袋，抑制IL -6诱导的STAT3磷酸化和HepG2细胞的核易位。C188在体外诱导乳腺癌细胞MB-MDA-468 的凋亡中表现出较高的活性(EC50= 0.7 μM)。

C188(Synonyms: CPD188)

C188 Chemical Structure

CAS No. : 823828-18-8

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

C188 is a STAT3 inhibitor that inhibits IL-6-stimulated STAT3 phosphorylation and nuclear translocation in HepG2 cells by targeting STAT3 SH2 domain peptide-binding pocket. C188, in particular, was highly active in inducing apoptosis of the breast cancer cell line MB-MDA-468 in vitro (EC50= 0.7 μM).

分子量

433.45

Formula

C19H15NO7S2
CAS 号

823828-18-8
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Xu X, Kasembeli MM, Jiang X, Tweardy BJ, Tweardy DJ. Chemical probes that competitively and selectively inhibit Stat3 activation. PLoS One. 2009;4(3):e4783.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

C188(Synonyms: CPD188)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

C188 (Synonyms: CPD188)

C188是一种STAT3抑制剂，通过靶向STAT3 SH2结构域的肽结合口袋，抑制IL -6诱导的STAT3磷酸化和HepG2细胞的核易位。C188在体外诱导乳腺癌细胞MB-MDA-468 的凋亡中表现出较高的活性(EC50= 0.7 μM)。

C188(Synonyms: CPD188)

C188 Chemical Structure

CAS No. : 823828-18-8

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

C188 is a STAT3 inhibitor that inhibits IL-6-stimulated STAT3 phosphorylation and nuclear translocation in HepG2 cells by targeting STAT3 SH2 domain peptide-binding pocket. C188, in particular, was highly active in inducing apoptosis of the breast cancer cell line MB-MDA-468 in vitro (EC50= 0.7 μM).

分子量

433.45

Formula

C19H15NO7S2
CAS 号

823828-18-8
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Xu X, Kasembeli MM, Jiang X, Tweardy BJ, Tweardy DJ. Chemical probes that competitively and selectively inhibit Stat3 activation. PLoS One. 2009;4(3):e4783.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

JAK2/STAT3-IN-1

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

JAK2/STAT3-IN-1 

JAK2/STAT3-IN-1 (compound (S)-10a) 是一种有效的 GP130 抑制剂，IC50 为 3.04 µM。JAK2/STAT3-IN-1 显示出抗肿瘤活性。

JAK2/STAT3-IN-1

JAK2/STAT3-IN-1 Chemical Structure

CAS No. : 2485758-50-5

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

JAK2/STAT3-IN-1 (compound (S)-10a) is a potent GP130 inhibitor with an IC50 of 3.04 µM. JAK2/STAT3-IN-1 shows anti-tumor activity[1].

IC50 & Target

IC50: 3.04 µM (GP130)[1]
分子量

682.57

Formula

C34H35BrF3N5O2
CAS 号

2485758-50-5
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Song D, et al. Discovery of bazedoxifene analogues targeting glycoprotein 130. Eur J Med Chem. 2020 Aug 1;199:112375.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

STAT3-IN-10

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

STAT3-IN-10 

STAT3-IN-10 (A11) 是一个 IC50 值为5.18 µM 的 STAT3 抑制剂。STAT3-IN-10 与 STAT3 SH2 结构域直接结合，抑制肿瘤细胞生长和诱导肿瘤细胞的凋亡 (apoptosis)

STAT3-IN-10

STAT3-IN-10 Chemical Structure

CAS No. : 2499491-04-0

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

STAT3-IN-10 (A11) is a STAT3 inhibitor with an IC50 value of 5.18 µM. STAT3-IN-10 directly binds to STAT3 SH2 domain, inhibits tumor cell growth and induces apoptosis in cancer cells[1].

IC50 & Target

STAT3

5.18 μM (IC50)

体外研究
(In Vitro)

STAT3-IN-10 (A11) (48 h) shows IC50 values of 0.67, 0.77, 1.24 µM against MDA-MB-231, MDA-MB-468, HepG2 cells, respectively[1].
STAT3-IN-10 (A11) directly binds to the STAT3 SH2 domain [1].
STAT3-IN-10 (A11) (0-3 μM, 24 h) inhibits the phosphorylation of STAT3 and its downstream target proteins and has a good selectivity against the tumor suppressor STAT1 [1].
STAT3-IN-10 (A11) (0-4 μM, 24 h) induces apoptosis in cancer cells[1].
STAT3-IN-10 (A11) (0-4 μM, 24 h) dose-dependently causes a significant S phase arrest in MDA-MB-231 cells[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: Breast cancer cell lines: MDA-MB-231 and MDA-MB-468; human liver carcinoma cell line: HepG2.
Concentration:
Incubation Time: 48 h, re-incubated for 4 h (MDA-MB-468, MDA-MB-231) and 1h (HepG2).
Result: Showed IC50 values of 0.67, 0.77, 1.24 µM against MDA-MB-231, MDA-MB-468, HepG2 cells, respectively.

Western Blot Analysis[1]

Cell Line: MDA-MB-231.
Concentration: 0, 0.75, 1.5 and 3.0 μM.
Incubation Time: 24 h.
Result: Decreased the STAT3-Y705 phosphorylation without affecting the total amount of STAT3 protein and decreased the expression of STAT3 target genes, including C-Myc and Cyclin D1 in a dose-dependent manner. Had little impact on the level of STAT1 and its phosphorylation on Tyr701.

Apoptosis Analysis[1]

Cell Line: MDA-MB-231.
Concentration: 0, 1, 2, and 4 μM.
Incubation Time: 24 h.
Result: Induced the apoptosis in MDA-MB-231 cells in a concentration-dependent manner

Cell Cycle Analysis[1]

Cell Line: MDA-MB-231.
Concentration: 0, 1, 2, and 4 μM.
Incubation Time: 24 h.
Result: Could dose-dependently cause a significant S phase arrest in MDA-MB-231 cells

体内研究
(In Vivo)

STAT3-IN-10 (A11) (5 and 10 mg/kg; IP; once a day, 21 days) inhibits the growth of human xenograft tumor in vivo[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Five weeks old female BALB/c nude mice (16–18g) bearing inoculation of human breast cancer cells MDA-MB-231[1].
Dosage: 5 and 10 mg/kg
Administration: IP, once a day, 21 days
Result: Inhibited the growth of human xenograft tumor in vivo without apparent body-weight loss for treated mice and inhibited the levels of p-STAT3 in tumor tissues.

分子量

311.29

Formula

C17H13NO5
CAS 号

2499491-04-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Kai-Rui Feng, et al. Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy. Eur J Med Chem. 2020 Sep 1;201:112428.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

STAT3-IN-10

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

STAT3-IN-10 

STAT3-IN-10 (A11) 是一个 IC50 值为5.18 µM 的 STAT3 抑制剂。STAT3-IN-10 与 STAT3 SH2 结构域直接结合，抑制肿瘤细胞生长和诱导肿瘤细胞的凋亡 (apoptosis)

STAT3-IN-10

STAT3-IN-10 Chemical Structure

CAS No. : 2499491-04-0

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

STAT3-IN-10 (A11) is a STAT3 inhibitor with an IC50 value of 5.18 µM. STAT3-IN-10 directly binds to STAT3 SH2 domain, inhibits tumor cell growth and induces apoptosis in cancer cells[1].

IC50 & Target

STAT3

5.18 μM (IC50)

体外研究
(In Vitro)

STAT3-IN-10 (A11) (48 h) shows IC50 values of 0.67, 0.77, 1.24 µM against MDA-MB-231, MDA-MB-468, HepG2 cells, respectively[1].
STAT3-IN-10 (A11) directly binds to the STAT3 SH2 domain [1].
STAT3-IN-10 (A11) (0-3 μM, 24 h) inhibits the phosphorylation of STAT3 and its downstream target proteins and has a good selectivity against the tumor suppressor STAT1 [1].
STAT3-IN-10 (A11) (0-4 μM, 24 h) induces apoptosis in cancer cells[1].
STAT3-IN-10 (A11) (0-4 μM, 24 h) dose-dependently causes a significant S phase arrest in MDA-MB-231 cells[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: Breast cancer cell lines: MDA-MB-231 and MDA-MB-468; human liver carcinoma cell line: HepG2.
Concentration:
Incubation Time: 48 h, re-incubated for 4 h (MDA-MB-468, MDA-MB-231) and 1h (HepG2).
Result: Showed IC50 values of 0.67, 0.77, 1.24 µM against MDA-MB-231, MDA-MB-468, HepG2 cells, respectively.

Western Blot Analysis[1]

Cell Line: MDA-MB-231.
Concentration: 0, 0.75, 1.5 and 3.0 μM.
Incubation Time: 24 h.
Result: Decreased the STAT3-Y705 phosphorylation without affecting the total amount of STAT3 protein and decreased the expression of STAT3 target genes, including C-Myc and Cyclin D1 in a dose-dependent manner. Had little impact on the level of STAT1 and its phosphorylation on Tyr701.

Apoptosis Analysis[1]

Cell Line: MDA-MB-231.
Concentration: 0, 1, 2, and 4 μM.
Incubation Time: 24 h.
Result: Induced the apoptosis in MDA-MB-231 cells in a concentration-dependent manner

Cell Cycle Analysis[1]

Cell Line: MDA-MB-231.
Concentration: 0, 1, 2, and 4 μM.
Incubation Time: 24 h.
Result: Could dose-dependently cause a significant S phase arrest in MDA-MB-231 cells

体内研究
(In Vivo)

STAT3-IN-10 (A11) (5 and 10 mg/kg; IP; once a day, 21 days) inhibits the growth of human xenograft tumor in vivo[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Five weeks old female BALB/c nude mice (16–18g) bearing inoculation of human breast cancer cells MDA-MB-231[1].
Dosage: 5 and 10 mg/kg
Administration: IP, once a day, 21 days
Result: Inhibited the growth of human xenograft tumor in vivo without apparent body-weight loss for treated mice and inhibited the levels of p-STAT3 in tumor tissues.

分子量

311.29

Formula

C17H13NO5
CAS 号

2499491-04-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Kai-Rui Feng, et al. Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy. Eur J Med Chem. 2020 Sep 1;201:112428.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

STAT3-IN-10

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

STAT3-IN-10 

STAT3-IN-10 (A11) 是一个 IC50 值为5.18 µM 的 STAT3 抑制剂。STAT3-IN-10 与 STAT3 SH2 结构域直接结合，抑制肿瘤细胞生长和诱导肿瘤细胞的凋亡 (apoptosis)

STAT3-IN-10

STAT3-IN-10 Chemical Structure

CAS No. : 2499491-04-0

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

STAT3-IN-10 (A11) is a STAT3 inhibitor with an IC50 value of 5.18 µM. STAT3-IN-10 directly binds to STAT3 SH2 domain, inhibits tumor cell growth and induces apoptosis in cancer cells[1].

IC50 & Target

STAT3

5.18 μM (IC50)

体外研究
(In Vitro)

STAT3-IN-10 (A11) (48 h) shows IC50 values of 0.67, 0.77, 1.24 µM against MDA-MB-231, MDA-MB-468, HepG2 cells, respectively[1].
STAT3-IN-10 (A11) directly binds to the STAT3 SH2 domain [1].
STAT3-IN-10 (A11) (0-3 μM, 24 h) inhibits the phosphorylation of STAT3 and its downstream target proteins and has a good selectivity against the tumor suppressor STAT1 [1].
STAT3-IN-10 (A11) (0-4 μM, 24 h) induces apoptosis in cancer cells[1].
STAT3-IN-10 (A11) (0-4 μM, 24 h) dose-dependently causes a significant S phase arrest in MDA-MB-231 cells[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: Breast cancer cell lines: MDA-MB-231 and MDA-MB-468; human liver carcinoma cell line: HepG2.
Concentration:
Incubation Time: 48 h, re-incubated for 4 h (MDA-MB-468, MDA-MB-231) and 1h (HepG2).
Result: Showed IC50 values of 0.67, 0.77, 1.24 µM against MDA-MB-231, MDA-MB-468, HepG2 cells, respectively.

Western Blot Analysis[1]

Cell Line: MDA-MB-231.
Concentration: 0, 0.75, 1.5 and 3.0 μM.
Incubation Time: 24 h.
Result: Decreased the STAT3-Y705 phosphorylation without affecting the total amount of STAT3 protein and decreased the expression of STAT3 target genes, including C-Myc and Cyclin D1 in a dose-dependent manner. Had little impact on the level of STAT1 and its phosphorylation on Tyr701.

Apoptosis Analysis[1]

Cell Line: MDA-MB-231.
Concentration: 0, 1, 2, and 4 μM.
Incubation Time: 24 h.
Result: Induced the apoptosis in MDA-MB-231 cells in a concentration-dependent manner

Cell Cycle Analysis[1]

Cell Line: MDA-MB-231.
Concentration: 0, 1, 2, and 4 μM.
Incubation Time: 24 h.
Result: Could dose-dependently cause a significant S phase arrest in MDA-MB-231 cells

体内研究
(In Vivo)

STAT3-IN-10 (A11) (5 and 10 mg/kg; IP; once a day, 21 days) inhibits the growth of human xenograft tumor in vivo[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Five weeks old female BALB/c nude mice (16–18g) bearing inoculation of human breast cancer cells MDA-MB-231[1].
Dosage: 5 and 10 mg/kg
Administration: IP, once a day, 21 days
Result: Inhibited the growth of human xenograft tumor in vivo without apparent body-weight loss for treated mice and inhibited the levels of p-STAT3 in tumor tissues.

分子量

311.29

Formula

C17H13NO5
CAS 号

2499491-04-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Kai-Rui Feng, et al. Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy. Eur J Med Chem. 2020 Sep 1;201:112428.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

AC-4-130

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

AC-4-130  纯度: 99.87%

AC-4-130 是一种有效的 STAT5 SH2 结构域抑制剂。AC-4-130 直接与 STAT5 结合并破坏 STAT5 激活、二聚化、核易位和 STAT5 依赖性基因转录。AC-4-130 在 FLT3-ITD 驱动的白血病细胞中诱导细胞周期停滞和细胞凋亡。AC-4-130 具有抗癌活性，可以有效阻断急性髓系白血病 (AML) 中 STAT5 活性的病理水平。

AC-4-130

AC-4-130 Chemical Structure

CAS No. : 1834571-82-2

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
5 mg ￥2500 In-stock
10 mg ￥3800 In-stock
25 mg ￥7500 In-stock
50 mg ￥13000 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

AC-4-130 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • JAK/STAT Compound Library
  • Kinase Inhibitor Library
  • Stem Cell Signaling Compound Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Differentiation Inducing Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Transcription Factor Targeted Library

生物活性

AC-4-130 is a potent STAT5 SH2 domain inhibitor. AC-4-130 directly binds to STAT5 and disrupts STAT5 activation, dimerization, nuclear translocation, and STAT5-dependent gene transcription. AC-4-130 induces cell cycle arrest and apoptosis in FLT3-ITD-driven leukemic cells. AC-4-130 has anti-cancer activity and can efficiently block pathological levels of STAT5 activity in acute myeloid leukemia (AML)[1].

IC50 & Target[1]

STAT5

 

体外研究
(In Vitro)

AC-4-130 (0.1-100 µM; 72 hours) leads to a significant increase in apoptosis in a dose-dependent and time-dependent manner in MV4-11 or MOLM-13 cells[1].
AC-4-130 (2, 5 µM; 72 hours) induces cell cycle arrest with an increase in G0/G1 arrested cells and a concomitant reduction in cells in S or G2/M[1].
AC-4-130 (0.5-2; 24 hours) reveals reduced pY-STAT5 levels both in the cytoplasm and nucleus[1].
AC-4-130-mediated STAT5 inhibition efficiently blocks the proliferation and clonogenic growth of primary human AML cells, while healthy CD34+ cells are less sensitive[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

751.20

Formula

C37H36ClF5N2O5S
CAS 号

1834571-82-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (133.12 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.3312 mL 6.6560 mL 13.3120 mL
5 mM 0.2662 mL 1.3312 mL 2.6624 mL
10 mM 0.1331 mL 0.6656 mL 1.3312 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (3.33 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.33 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Bettina Wingelhofer, et al. Pharmacologic inhibition of STAT5 in acute myeloid leukemia. Leukemia. 2018 May;32(5):1135-1146.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务